A phase 1a/b clinical trial showed that pamiparib, an oral PARP 1/2 inhibitor, with tislelizumab, a humanised anti-PD-1 monoclonal antibody, was generally well tolerated and had an ORR of 20% in patients with a variety of advanced solid tumors, including ovarian cancer (175). Here, PDCD1 is linked to ovarian carcinoma.